Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 06/17/2027 | CALL | $1,100.00 | 1,312 | +891 | +211.64% |
| 07/17/2026 | PUT | $840.00 | 1,374 | +470 | +51.99% |
| 05/08/2026 | CALL | $990.00 | 565 | +390 | +222.86% |
| 06/05/2026 | PUT | $895.00 | 277 | +243 | +714.71% |
| 06/17/2027 | PUT | $1,060.00 | 210 | +204 | +3,400.00% |
| 05/08/2026 | PUT | $737.50 | 234 | +196 | +515.79% |
| 06/18/2026 | CALL | $1,000.00 | 1,901 | -58 | -2.96% |
| 05/15/2026 | CALL | $1,000.00 | 2,819 | -67 | -2.32% |
| 05/15/2026 | CALL | $1,100.00 | 2,005 | -78 | -3.74% |
| 05/15/2026 | CALL | $1,070.00 | 472 | -81 | -14.65% |
| 06/18/2026 | CALL | $800.00 | 666 | -150 | -18.38% |
| 06/18/2026 | CALL | $1,140.00 | 701 | -290 | -29.26% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
05/08 09:30 am
The Motley Fool
Read moreNarrow Tech Leadership Continues as Oil and Rates Fall
05/07 02:43 am
Investing.com
Read moreWegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook
05/06 07:43 am
Benzinga
Read moreEli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
05/05 10:55 am
Benzinga
Read more3 Reasons It's Not Too Late to Buy Eli Lilly Stock
05/04 08:30 pm
The Motley Fool
Read moreIs Eli Lilly Stock Heading for $1,000?
05/04 05:30 pm
The Motley Fool
Read moreLilly declares second-quarter 2026 dividend
05/04 11:11 am
Benzinga
Read morePfizer Stock: Still Priced Like It's Dead Money
05/03 07:15 pm
The Motley Fool
Read more$9 Trillion Is Pouring Into American Manufacturing — And It’s Just Getting Started
05/03 06:00 pm
GlobeNewswire Inc.
Read moreLilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
05/01 02:45 pm
Investing.com
Read moreDeal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy
05/01 02:35 pm
Benzinga
Read moreStock Market Today: Dow, S&P 500, Nasdaq Futures RiseAs Trump Administration Evades War Powers Deadline— Apple, Twilio, Roblox In Focus (UPDATED)
05/01 08:41 am
Benzinga
Read moreNxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
05/01 02:36 am
GlobeNewswire Inc.
Read moreStock Market Today: Dow Jones Roars As Industrials Rescue Wall Street From Meta-Led Tech Slide
04/30 01:09 pm
Benzinga
Read moreEli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
04/30 12:03 pm
Benzinga
Read moreWhat's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
04/30 05:10 am
The Motley Fool
Read moreRetatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
04/29 11:00 am
GlobeNewswire Inc.
Read moreIs Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So
04/28 06:15 pm
The Motley Fool
Read moreRheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
04/28 01:00 pm
GlobeNewswire Inc.
Read moreIs This Deal a Game Changer for Novo Nordisk?
04/27 08:30 pm
The Motley Fool
Read moreForget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly
04/27 08:15 pm
The Motley Fool
Read moreMag 7 Earnings Bonanza, Fed Await Stocks at Record Highs: What to Expect
04/27 05:36 am
Investing.com
Read moreIs SpaceX Really Worth $1.75 Trillion -- or Is That Actually Too Low?
04/27 05:11 am
The Motley Fool
Read moreThis Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street
04/26 10:02 am
The Motley Fool
Read moreShould You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?
04/25 07:05 pm
The Motley Fool
Read moreIs This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?
04/25 01:05 pm
The Motley Fool
Read moreWhy Eli Lilly Stock Flopped on Friday
04/24 06:30 pm
The Motley Fool
Read moreDeal Dispatch: QXO Nabs TopBuild For $17 Million, Voya Financial Urged To Evaluate Strategic Options, Pat McGrath Exits Chapter 11
04/24 02:27 pm
Benzinga
Read moreRadiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand
04/24 09:57 am
GlobeNewswire Inc.
Read moreOmics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
04/24 04:59 am
GlobeNewswire Inc.
Read moreHims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
04/23 12:19 pm
Benzinga
Read moreKailera Therapeutics' Strong IPO Validates "NewCo" Strategy
04/23 12:08 pm
Benzinga
Read moreIs Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
04/23 09:30 am
The Motley Fool
Read moreForget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
04/23 05:30 am
The Motley Fool
Read more3 Healthcare Stocks With the Most Durable Competitive Moats
04/23 04:05 am
The Motley Fool
Read moreLarge Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
04/22 02:20 pm
Benzinga
Read moreWhy Did Eli Lilly Stock Drop Today?
04/21 10:35 am
The Motley Fool
Read moreA Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
04/21 07:30 am
The Motley Fool
Read moreWhy Legend Biotech Stock Crushed the Market on Monday
04/20 06:16 pm
The Motley Fool
Read moreWill Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?
04/20 10:15 am
The Motley Fool
Read moreThis Drug Stock Has Crushed the S&P 500 Over the Last Decade
04/18 05:15 pm
The Motley Fool
Read moreDeal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy
04/17 02:33 pm
Benzinga
Read moreKailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race
04/17 01:23 pm
Benzinga
Read moreNovo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
04/17 12:04 pm
Benzinga
Read moreChina Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi
04/17 12:00 pm
GlobeNewswire Inc.
Read moreIs Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
04/17 05:10 am
The Motley Fool
Read moreNon-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight
04/16 01:00 pm
GlobeNewswire Inc.
Read moreEli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
04/16 10:16 am
Benzinga
Read more